{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:36:38Z","timestamp":1787016998041,"version":"build-2736575974"},"reference-count":13,"publisher":"BMJ","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Occup Environ Med"],"published-print":{"date-parts":[[2001,6,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVES<\/jats:title>\n                    <jats:p>To study the routine diagnostic procedures used in different countries for chronic toxic encephalopathy (CTE) induced by solvents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec sec-type=\"methods\">\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>By means of a postal questionnaire selected international experts were asked about the methods they use to diagnose patients suspected of having CTE induced by solvents, the number of patients, entrance criteria, and the results of these diagnostic procedures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>18 Experts working in 18 diagnostic centres responded. Most of them agreed that a diagnostic procedure for CTE induced by solvents should contain an interview and neurological, physical, and neuropsychological examinations. However, the tests used were very different, as were the classifications for CTE. Depending on the institute, a diagnosis of CTE was made in 6%\u201370% of the referred patients. The proportion of patients with CTE stage I ranged from 0% to 33%, stage II from 5% to 100%, and stage III from 0% to 95%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>The intentions of the two 1985 conferences that aimed at clarity and uniformity of diagnosis of CTE induced by solvents are far from reached. It is possible, now the conditions are more favourable, to aim at this important goal and recommend some refinement of the then proposed criteria.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/oem.58.6.382","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T06:38:40Z","timestamp":1027751920000},"page":"382-385","source":"Crossref","is-referenced-by-count":17,"title":["Routine diagnostic procedures for chronic encephalopathy induced by solvents: survey of experts"],"prefix":"10.1136","volume":"58","author":[{"given":"J A F","family":"van der Hoek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M M","family":"Verberk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"van der Laan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Hageman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2001,6,1]]},"reference":[{"key":"2024052310523598000_58.6.382.1","first-page":"59","article-title":"Has the Scandinavian solvent syndrome controversy been solved?","volume":"20","author":"Hogstedt","year":"1994","journal-title":"Scand J Work Environ Health"},{"key":"2024052310523598000_58.6.382.2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-4679(199711)53:7<699::AID-JCLP7>3.0.CO;2-D"},{"key":"2024052310523598000_58.6.382.3","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1006\/enrs.1993.1019","article-title":"Neurotoxic syndromes and occupational exposure to solvents.","volume":"60","author":"Juntunen","year":"1993","journal-title":"Environ Res"},{"key":"2024052310523598000_58.6.382.4","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1006\/enrs.1997.3706","article-title":"Epidemiological update on solvent neurotoxicity.","volume":"73","author":"Mikkelsen","year":"1997","journal-title":"Environ Res"},{"key":"2024052310523598000_58.6.382.5","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/00043764-199005000-00010","article-title":"Alterations in cognitive and psychological functioning after organic solvent exposure.","volume":"32","author":"Morrow","year":"1990","journal-title":"J Occup Med"},{"key":"2024052310523598000_58.6.382.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)07218-2"},{"key":"2024052310523598000_58.6.382.7","unstructured":"(1987) Current Intelligence Bulletin 48. Organic solvent neurotoxicity. (USDHHS\/PHS\/CDC\/NIOSH, Cincinnati) . (DHHS Publ No. 87\u00e2\u0080\u0093104.)."},{"key":"2024052310523598000_58.6.382.8","first-page":"425","article-title":"Chronic solvent neurotoxicity in New Zealand: notified cases between 1993 and 1997.","volume":"111","author":"Dryson","year":"1998","journal-title":"N Z Med J"},{"key":"2024052310523598000_58.6.382.9","unstructured":"World Health Organization (1985) Chronic effects of organic solvents on the central nervous system and diagnostic criteria. (WHO, Copenhagen), pp 1\u00e2\u0080\u009339, . (Environmental Health 5.)."},{"key":"2024052310523598000_58.6.382.10","first-page":"45","article-title":"Workshop on neurobehavioral effects of solvents. Human aspects of solvent neurobehavioral effects.","volume":"7","author":"Baker","year":"1986","journal-title":"Neurotoxicology"},{"key":"2024052310523598000_58.6.382.11","doi-asserted-by":"crossref","unstructured":"Hoek JAF van der, Verberk MM, Hageman G. Criteria for solvent-induced chronic toxic encephalopathy: a systematic review.Int Arch Occup Environ Health2000;73:362\u00e2\u0080\u00938..","DOI":"10.1007\/s004200000119"},{"key":"2024052310523598000_58.6.382.12","unstructured":"(1994) Quick reference to the diagnostic criteria from DSM-IV. (American Psychiatric Association, Washington, DC)."},{"key":"2024052310523598000_58.6.382.13","doi-asserted-by":"publisher","DOI":"10.1007\/s004200000179"}],"container-title":["Occupational and Environmental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/oem.58.6.382","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T14:52:52Z","timestamp":1716475972000},"score":1,"resource":{"primary":{"URL":"https:\/\/oem.bmj.com\/lookup\/doi\/10.1136\/oem.58.6.382"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,6,1]]},"references-count":13,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2001,6,1]]},"published-print":{"date-parts":[[2001,6,1]]}},"alternative-id":["10.1136\/oem.58.6.382"],"URL":"https:\/\/doi.org\/10.1136\/oem.58.6.382","relation":{},"ISSN":["1351-0711","1470-7926"],"issn-type":[{"value":"1351-0711","type":"print"},{"value":"1470-7926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,6,1]]}}}